THIS REPORT



Discussion of ophthalmology drug products for such diseases as wet and dry age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and dry-eye; therapeutics for other diseases examined via qualitative analysis include those for conjunctiva, scleritis, macular edema, Usher's syndrome, and uveitis

Analysis of market trends, with data for 2008, estimates for 2009, and projections of compound annual growth rates (CAGRs) through 2014

A focus on salient manufacturers, technologies, geographies, and factors influencing demand

Comprehensive company profiles.

Table Of Contents

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
INFORMATION SOURCES 4
RELATED BCC REPORTS 4
BCC ONLINE SERVICES 5
DISCLAIMER 5

Chapter-2: EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, 2008-2014 ($ MILLIONS) 7
EXECUTIVE SUMMARY (CONTINUED) 8

Chapter-3: OVERVIEW

HISTORY AND CURRENT STATE OF OPHTHALMOLOGY DISEASE 9
ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY 10
EMERGING DRUG CLASSES 10
VEGF-Trap Eye 10
Combination Therapies 10
COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD 11
TABLE 1 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN: PREVIOUS AND EXPECTED 11
TABLE 1 (CONTINUED) 12
Expected Outcome of CATT trial: Avastin v. Lucentis 12
GENETIC SPECIFICATIONS OF OPHTHALMIC DISEASE 13
TABLE 2 SUMMARY OF KNOWN GENES INFLUENCING DISEASE 13
TABLE 2 (CONTINUED) 14
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 14
TABLE 3 RECENTLY APPROVED DRUGS, 2009 14
TABLE 4 SUMMARY PIPELINE FORECAST, 2012-2014 15

Chapter-4: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE 16
MARKET CONCENTRATION AND PRICE SENSITIVITY 16
TABLE 5 COMPANY BY DISEASE CLASS, 2009 REVENUE ($ MILLIONS) 17
COMPETITIVE FACTORS 18
TABLE 6 LARGE REVENUE, BRANDED DRUG SALES COMING OFF PATENT, 2009 18
MARKET TRENDS 18
Demographics Offer Tremendous Long-run Opportunity 18
TABLE 7 REVENUE GROWTH OF OPHTHALMOLOGY AS COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2009 (% YEAR-OVER-YEAR REVENUE GROWTH) 19
An Increasingly Challenging Global Reimbursement Environment 19
Sustained Drug Delivery Is the Future of Retinal Care 20
Payment Structures Are Ever More Important to Revenue Uptake and Peak Sales. 20
Fundamental Patient Need: Blindness or Impaired Vision Are Among the Most Debilitating Diseases 21
Combination Therapies Promise Improved Therapeutic Response 21
Expansion of Prescription Therapies to Rural Communities 21
TABLE 8 NUMBER OF U.S. HOSPITALS PROVIDING OPHTHALMIC CARE 22
TABLE 9 NUMBER OF TRAINED, LICENSED, AND CERTIFIED OPHTHALMOLOGISTS 22
TABLE 10 MARKET REVENUE AND SHARE BY LEADING OPHTHALMIC PLAYERS, 2009 ($ MILLIONS/%) 23
TABLE 11 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 ($ MILLIONS) 23
TABLE 12 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT, 2009 ($ MILLIONS/%) 24
NOTABLE MERGERS, ACQUISITIONS AND TRANSACTIONS 24
Roche/Genentech 24
Alcon/Novartis 25
Transaction Summary 25
Proposed Terms of Purchase 25
Integration Challenges and Opportunities 26
Fovea/Sanofi-Aventis 26
Fovea/Sanofi-Aventis (Continued) 27

Chapter-5: MARKETS BY DISEASE

SUMMARY OF MARKET DYNAMICS 28
TABLE 13 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 ($ MILLIONS) 29
AMD 29
PATHOPHYSIOLOGY AND PATHOGENESIS 29
Pathophysiology and Pathogenesis (Continued) 30
TREATMENT AND MANAGEMENT 31
Wet AMD 31
Wet AMD (Continued) 32
Dry AMD 33
FORECAST EPIDEMIOLOGY 33
TABLE 14   GLOBAL FORECAST EPIDEMIOLOGY: WET AMD, PREVALENCE, THROUGH 2014 33
TABLE 15 WET AMD REVENUE, 2009 SUMMARY, 2008 AND 2009 ($ MILLIONS) 34
TABLE 16 WET AMD, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 34
TABLE 17 WET AMD REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 35
TABLE 18   GLOBAL FORECAST EPIDEMIOLOGY: DRY AMD, PREVALENCE, THROUGH 2014 35
GLAUCOMA 35
PATHOPHYSIOLOGY AND PATHOGENESIS 35
Pathophysiology and Pathogenesis (Continued) 36
TREATMENT AND MANAGEMENT 37
Xalatan 37
Cosopt 38
Travatan 39
Lumigan 39
Lumigan (Continued) 40
Prostaglandins Analysis: First Line Treatment for Glaucoma 41
GLAUCOMA MANAGEMENT STRATEGIES 41
Combination Therapies in Glaucoma Management 41
FORECAST EPIDEMIOLOGY 42
TABLE 19   GLOBAL FORECAST EPIDEMIOLOGY: GLAUCOMA, PREVALENCE, THROUGH 2014 42
TABLE 20 GLAUCOMA REVENUE, 2009 SUMMARY ($ MILLIONS) 43
TABLE 21 GLAUCOMA, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 43
TABLE 22 GLAUCOMA REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 44
DIABETIC RETINOPATHY 44
PATHOPHYSIOLOGY AND PATHOGENESIS 44
Pathophysiology and Pathogenesis (Continued) 45
TABLE 23 SUCCESSIVE STAGES OF DIABETIC RETINOPATHY 46
TREATMENT AND MANAGEMENT 46
Avastin 46
Arxxant 47
Iluvien 47
FORECAST EPIDEMIOLOGY 48
TABLE 24   GLOBAL FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, PREVALENCE, THROUGH 2014 48
DRY-EYE DISEASE 48
PATHOPHYSIOLOGY AND PATHOGENESIS 48
TREATMENT AND MANAGEMENT 49
Restasis 49
Hyalein 50
Regulatory Update for Dry-eye Disease 51
FORECAST EPIDEMIOLOGY 52
TABLE 25   GLOBAL FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, PREVALENCE, THROUGH 2014 52
TABLE 26 DRY-EYE DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS/%) 53
TABLE 27 DRY-EYE DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 53
TABLE 28 DRY-EYE DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 54
ALLERGIC DISEASES 54
TABLE 29 ALLERGIC DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS/%) 55
TABLE 30 ALLERGIC DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS/%) 55
TABLE 31 ALLERGIC DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 56
INFECTIOUS DISEASES 56
TABLE 32 INFECTIOUS DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS) 57
TABLE 33   INFECTIOUS DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 57
TABLE 34   INFECTIOUS DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 58
INFLAMMATORY DISEASE 58
TABLE 35 INFLAMMATORY DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS/%) 59
TABLE 36   INFLAMMATORY DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 60
TABLE 37 INFLAMMATORY DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 60
COMBINATION INFECTIOUS AND INFLAMMATORY DISEASE 60
TABLE 38   DUAL INFLAMMATORY AND INFECTIVE DISEASE REVENUE, 2009 SUMMARY ($ MILLIONS) 61
TABLE 39 DUAL INFLAMMATORY AND INFECTIVE DISEASE, FORECAST BY COMPANY, THROUGH 2014 ($ MILLIONS) 62
TABLE 40 DUAL INFLAMMATORY AND INFECTIVE DISEASE REVENUE, FORECAST BY DRUG, THROUGH 2014 ($ MILLIONS) 62
OTHER OPHTHALMIC PRESCRIPTION TREATMENTS 62
ADDITIONAL DISEASES 62
Uveitis 62
Scleritis (Noninfectious and Infectious) 63
Usher Syndrome 64
Coat’s Disease 64
Eales Disease 65
Corneal Abrasion 65
Fuchs’ Endothelial Dystrophy 66
Hypertensive Retinopathy 66
Stargardt’s Disease (Juvenile Macular Degeneration) 66
Thygeson’s Superficial Punctate Keratopathy 67

Chapter-6: MARKETS BY GEOGRAPHY

SUMMARY 68
METHODOLOGY 68
MARKET SIZING DEFINITIONS 69
UNITED STATES 69
TABLE 41   FORECAST U.S. EPIDEMIOLOGY: WET AMD, THROUGH 2014 70
TABLE 42    FORECAST U.S. EPIDEMIOLOGY: DRY AMD, THROUGH 2014 70
TABLE 43 FORECAST U.S. EPIDEMIOLOGY: GLAUCOMA, THROUGH 2014 70
TABLE 44 FORECAST U.S. EPIDEMIOLOGY: DRY-EYE DISEASE, THROUGH 2014 71
TABLE 45    FORECAST U.S. EPIDEMIOLOGY: DIABETIC RETINOPATHY, THROUGH 2014 71
WESTERN EUROPE 71
TABLE 46   FORECAST EPIDEMIOLOGY: WET AMD IN WESTERN EUROPE, THROUGH 2014 72
TABLE 47   FORECAST EPIDEMIOLOGY: DRY AMD IN WESTERN EUROPE, THROUGH 2014 72
TABLE 48 FORECAST EPIDEMIOLOGY: GLAUCOMA IN WESTERN EUROPE, THROUGH 2014 73
TABLE 49 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN WESTERN EUROPE, THROUGH 2014 73
TABLE 50 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN WESTERN EUROPE, THROUGH 2014 73
JAPAN 73
TABLE 51 FORECAST EPIDEMIOLOGY: WET AMD IN JAPAN, THROUGH 2014 74
TABLE 52 FORECAST EPIDEMIOLOGY: DRY AMD IN JAPAN, THROUGH 2014 74
TABLE 53 FORECAST EPIDEMIOLOGY: GLAUCOMA IN JAPAN, THROUGH 2014 75
TABLE 54 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN JAPAN, THROUGH 2014 75
TABLE 55   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, THROUGH 2014 75
STRATEGIES TO ACCESS EMERGING MARKETS 75
STRATEGIES TO ACCESS EMERGING … (CONTINUED) 76
EMERGING MARKETS FORECAST 77
BRAZIL 77
MARKET OVERVIEW 77
REGULATORY CONSIDERATIONS 78
PATENT CONSIDERATIONS 78
TABLE 56 FORECAST EPIDEMIOLOGY: WET AMD IN BRAZIL, THROUGH 2014 78
TABLE 57   FORECAST EPIDEMIOLOGY: DRY AMD IN BRAZIL, THROUGH 2014 79
TABLE 58   FORECAST EPIDEMIOLOGY: GLAUCOMA, THROUGH 2014 79
TABLE 59 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN BRAZIL, THROUGH 2014 79
TABLE 60 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN BRAZIL, THROUGH 2014 80
CHINA 80
MARKET OVERVIEW 80
REGULATORY CONSIDERATIONS 80
PATENT CONSIDERATIONS 81
TABLE 61 FORECAST EPIDEMIOLOGY: WET AMD IN CHINA, THROUGH 2014 82
TABLE 62 FORECAST EPIDEMIOLOGY: DRY AMD IN CHINA, THROUGH 2014 82
TABLE 63 FORECAST EPIDEMIOLOGY: GLAUCOMA IN CHINA, THROUGH 2014 82
TABLE 64 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CHINA, THROUGH 2014 83
TABLE 65 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CHINA, THROUGH 2014 83
INDIA 83
MARKET OVERVIEW 83
REGULATORY CONSIDERATIONS 84
PATENT CONSIDERATIONS 84
TABLE 66 FORECAST EPIDEMIOLOGY: WET AMD IN INDIA, THROUGH 2014 85
TABLE 67 FORECAST EPIDEMIOLOGY: DRY AMD IN INDIA, THROUGH 2014 85
TABLE 68 FORECAST EPIDEMIOLOGY: GLAUCOMA IN INDIA, THROUGH 2014 85
TABLE 69 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN INDIA, THROUGH 2014 86
TABLE 70 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN INDIA, THROUGH 2014 86
RUSSIA 86
MARKET OVERVIEW 86
REGULATORY CONSIDERATIONS 87
PATENT CONSIDERATIONS 87
TABLE 71   FORECAST EPIDEMIOLOGY: WET AMD IN RUSSIA, THROUGH 2014 87
TABLE 72   FORECAST EPIDEMIOLOGY: DRY AMD IN RUSSIA, THROUGH 2014 88
TABLE 73 FORECAST EPIDEMIOLOGY: GLAUCOMA IN RUSSIA. THROUGH 2014 88
TABLE 74 FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN RUSSIA, THROUGH 2014 88
TABLE 75 FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN RUSSIA, THROUGH 2014 89
REGIONAL PREVALENCE FORECASTS 89
CENTRAL AMERICA 89
Mexico, Belize, Nicaragua, Guatemala 89
TABLE 76   FORECAST EPIDEMIOLOGY: WET AMD IN CENTRAL AMERICA, THROUGH 2014 89
TABLE 77   FORECAST EPIDEMIOLOGY: DRY AMD IN CENTRAL AMERICA, THROUGH 2014 89
TABLE 78   FORECAST EPIDEMIOLOGY: GLAUCOMA IN CENTRAL AMERICA, THROUGH 2014 90
TABLE 79   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN CENTRAL AMERICA, THROUGH 2014 90
TABLE 80   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN CENTRAL AMERICA. THROUGH 2014 90
SOUTH AMERICA 91
Panama, Uruguay, Costa Rica, El Salvador, Honduras, Ecuador, Argentina, Paraguay, Chile, Venezuela, Peru, Bolivia, Colombia 91
TABLE 81   FORECAST EPIDEMIOLOGY: WET AMD IN SOUTH AMERICA, THROUGH 2014 91
TABLE 82   FORECAST EPIDEMIOLOGY: DRY AMD IN SOUTH AMERICA, THROUGH 2014 91
TABLE 83   FORECAST EPIDEMIOLOGY: GLAUCOMA IN SOUTH AMERICA, THROUGH 2014 91
TABLE 84   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN SOUTH AMERICA, THROUGH 2014 92
TABLE 85   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN SOUTH AMERICA, THROUGH 2014 92
CARRIBEAN 92
Jamaica, Dominican Republic, Cuba, Trinidad and Tobago, Haiti, and 10 other Countries Comprising less than 20% of the Region’s Population 92
TABLE 86   FORECAST EPIDEMIOLOGY: WET AMD IN THE CARRIBEAN, THROUGH 2014 92
TABLE 87   FORECAST EPIDEMIOLOGY: DRY AMD IN THE CARRIBEAN, THROUGH 2014 93
TABLE 88   FORECAST EPIDEMIOLOGY: GLAUCOMA IN THE CARRIBEAN, THROUGH 2014 93
TABLE 89   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN THE CARRIBEAN THROUGH 2014 93
TABLE 90   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN THE CARRIBEAN, THROUGH 2014 94
NORTHERN EUROPE 94
Norway, Iceland, Finland, Denmark, Sweden 94
TABLE 91   FORECAST EPIDEMIOLOGY: WET AMD, NORTHERN EUROPE, THROUGH 2014 94
TABLE 92   FORECAST EPIDEMIOLOGY: DRY AMD, NORTHERN EUROPE, THROUGH 2014 94
TABLE 93   FORECAST EPIDEMIOLOGY: GLAUCOMA, NORTHERN EUROPE, THROUGH 2014 95
TABLE 94   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, NORTHERN EUROPE, THROUGH 2014 95
TABLE 95   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, NORTHERN EUROPE, THROUGH 2014 95
CENTRAL AND EASTERN EUROPE 96
Serbia, Liechtenstein, Estonia, Slovenia, Macedonia, Latvia, Albania, Lithuania, Bosnia and Herzegovina, Croatia, Georgia, Slovakia, Azerbaijan, Bulgaria, Belarus, Hungary, Czech Republic, Romania, Poland, Ukraine, Netherlands Antilles, Montenegro, Cyprus, Armenia, Turkmenistan 96
TABLE 96   FORECAST EPIDEMIOLOGY: WET AMD, CENTRAL AND EASTERN EUROPE, THROUGH 2014 96
TABLE 97   FORECAST EPIDEMIOLOGY: DRY AMD, CENTRAL AND EASTERN EUROPE, THROUGH 2014 96
TABLE 98   FORECAST EPIDEMIOLOGY: GLAUCOMA, CENTRAL AND EASTERN EUROPE, THROUGH 2014 96
TABLE 99   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, CENTRAL AND EASTERN EUROPE, THROUGH 2014 97
TABLE 100   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, CENTRAL AND EASTERN EUROPE, THROUGH 2014 97
AUSTRALIA 97
Australia, Guinea, New Zealand, Papua New Guinea, Pipeline Analysis 97
TABLE 101   FORECAST EPIDEMIOLOGY: WET AMD IN AUSTRALIA 97
TABLE 102   FORECAST EPIDEMIOLOGY: DRY AMD IN AUSTRALIA, THROUGH 2014 98
TABLE 103   FORECAST EPIDEMIOLOGY: GLAUCOMA IN AUSTRALIA, THROUGH 2014 98
TABLE 104   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE IN AUSTRALIA, THROUGH 2014 98
TABLE 105   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY IN AUSTRALIA, THROUGH 2014 99
ASIA-OTHER 99
Indonesia, Pakistan, Bangladesh, Philippines, Vietnam, Turkey, Thailand, South Korea, Burma, Nepal, Afghanistan, Uzbekistan, and 76 Other Countries Comprising 18% of the Region’s Population 99
TABLE 106   FORECAST EPIDEMIOLOGY: WET AMD, ASIA-OTHER, THROUGH 2014 99
TABLE 107   FORECAST EPIDEMIOLOGY: DRY AMD, ASIA-OTHER, THROUGH 2014 99
TABLE 108   FORECAST EPIDEMIOLOGY: GLAUCOMA, ASIA-OTHER, THROUGH 2014 100
TABLE 109   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, ASIA-OTHER, THROUGH 2014 100
TABLE 110   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, ASIA-OTHER, THROUGH 2014 100
MIDDLE EAST 101
United Arab Emirates, Saudi Arabia, Israel, Gaza Strip, Kuwait, West Bank, Lebanon, Jordan, Syria, Yemen, Iraq, Iran 101
TABLE 111   FORECAST EPIDEMIOLOGY: WET AMD, MIDDLE EAST, THROUGH 2014 101
TABLE 112   FORECAST EPIDEMIOLOGY: DRY AMD, MIDDLE EAST, THROUGH 2014 101
TABLE 113   FORECAST EPIDEMIOLOGY: GLAUCOMA, MIDDLE EAST, THROUGH 2014 101
TABLE 114   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, MIDDLE EAST, THROUGH 2014 102
TABLE 115   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, MIDDLE EAST, THROUGH 2014 102
SOUTHERN AFRICA 102
South Africa, Cape Verde, Malawi, Swaziland, Botswana, Zambia, Angola, Zimbabwe 102
TABLE 116   FORECAST EPIDEMIOLOGY: WET AMD, SOUTHERN AFRICA, THROUGH 2014 102
TABLE 117   FORECAST EPIDEMIOLOGY: DRY AMD, SOUTHERN AFRICA, THROUGH 2014 103
TABLE 118   FORECAST EPIDEMIOLOGY: GLAUCOMA, SOUTHERN AFRICA, THROUGH 2014 103
TABLE 119   FORECAST EPIDEMIOLOGY: DRY-EYE DISEASE, SOUTHERN AFRICA THROUGH 2014 103
TABLE 120   FORECAST EPIDEMIOLOGY: DIABETIC RETINOPATHY, SOUTHERN AFRICA, THROUGH 2014 104
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST 104

Chapter-7: PIPELINE ANALYSIS

TABLE 121 APPROVED PRODUCT SALES FORECAST, 2008-2014 ($ MILLIONS) 105
TABLE 122 PIPELINE SALES FORECAST, 2008-2014 ($ MILLIONS) 105
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 106
STRINGENT REGULATORY PATHWAY EXISTS FOR DRY-EYE DISEASE 106
Sustained Delivery Is a Common Trait Among Leading Products in Development 106
Sustained Delivery …(Continued) 107
SiRNA Therapies in Development Experience Systemic Safety Concerns 108
2009 APPROVALS IN OPHTHALMOLOGY THERAPY 109
ACUVAIL 109
TABLE 123 SNAPSHOT OF ACUVAIL 110
Clinical Results 110
BEPREVE 110
TABLE 124 SNAPSHOT OF BEPREVE 111
Clinical Results 111
BESIVANCE 111
TABLE 125 SNAPSHOT OF BESIVANCE 112
OZURDEX 113
TABLE 126 SNAPSHOT OF OZURDEX 113
ZIRGAN 114
OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT 115
PHASE III 115
VEGF Trap-Eye 115
TABLE 127 SNAPSHOT OF VEGF TRAP-EYE 116
Clinical Results 116
Iluvien 117
TABLE 128 SNAPSHOT OF ILUVIEN 117
Clinical Results 117
Luveniq 118
TABLE 129 SNAPSHOT OF LUVENIQ 118
PHASE II 119
Ecabet 119
TABLE 130 SNAPSHOT OF ECABET 119
Clinical Results 119
Androgen Tears 120
TABLE 131 SNAPSHOT OF ANDROGEN TEARS 120
PIPELINE ANALYSIS BY COMPANY 121
TABLE 132 ALCON’S OPHTHALMIC PIPELINE 121
TABLE 133 ALLERGAN’S OPHTHALMIC PIPELINE 121
TABLE 134 PFIZER’S OPHTHALMIC PIPELINE 121
TABLE 135 NOVARTIS’ OPHTHALMIC PIPELINE 122
TABLE 136 NOVARTIS’ OPHTHALMIC PIPELINE 122
TABLE 137 MERCK OPHTHALMIC PIPELINE 122
TABLE 138 SANTEN OPHTHALMIC PIPELINE 123

Chapter-8: COMPANY PROFILES

SUMMARY 124
ABBOT MEDICAL PRODUCTS 125
Business Overview 125
Leading Products 125
Corporate Strategy 125
ACUCELA 125
Business Overview 125
Leading Products 126
Corporate Strategy 126
AERIE PHARMA 126
Business Overview 127
Leading Products 127
Corporate Strategy 127
AKORN, INC. 127
Business Overview 128
Leading Products 128
Akten 128
Timolol Maleate 128
Corporate Strategy 128
ALCON 129
Business Overview 129
Leading Products 129
Pataday 130
Vigamox 130
Nevanac 130
Triesence 130
Tobradex 130
Travatan and Travatan Z 130
Azopt 131
Azarga 131
Duotrav 131
Corporate Strategy 131
ALIMERA SCIENCES 131
Business Overview 132
Leading Products 132
Iluvien 132
Other Products 132
Corporate Strategy 132
ALLERGAN, INC. 133
Business Overview 133
Leading Products 133
Restasis and Others 133
Lumigan and Others 133
Corporate Strategy 134
CAN-FITE BIOPHARMA LTD. 134
Business Overview 135
Leading Products 135
Corporate Strategy 135
COMENTIS 135
Business Overview 136
Leading Products 136
ATG-3 136
Corporate Strategy 136
DANUBE PHARMACEUTICALS 136
Business Overview 137
Leading Products 137
DNB-001 137
Corporate Strategy 137
ESBATECH 137
Business Overview 137
Leading Products 138
ESBA105 138
Corporate Strategy 138
EYEGATE PHARMA 138
Business Overview 138
Leading Products 138
EGP-437 138
Corporate Strategy 139
GENENTECH 139
Business Overview 139
Leading Products 139
Lucentis 139
Avastin (Bevacizumab) 140
Corporate Strategy 140
GENE SIGNAL 141
Business Overview 141
Leading Products 141
GS-101 141
Corporate Strategy 141
ICO THERAPEUTICS 142
Business Overview 142
Leading Products 142
Corporate Strategy 142
INSITE VISION 143
Business Overview 143
Leading Products 143
AzaSite 143
Corporate Strategy 143
INSPIRE PHARMACEUTICALS, INC 143
Business Overview 144
Leading Products 144
Prolacria (diquafosol tetrasodium) 144
Additional Products 144
Corporate Strategy 145
IRIDEX 145
Business Overview 145
Leading Products 145
Transpupillary Thermotherapy 145
Corporate Strategy 146
ISTA PHARMACEUTICALS 146
Business Overview 146
Leading Products 146
Bepreve 146
Xibrom 147
Istalol 147
Corporate Strategy 147
JERINI AG 147
Business Overview 147
Leading Products 148
a5ß1 Integrin (JSM 6427) 148
Corporate Strategy 148
LPATH INCORPORATED 148
Business Overview 148
Leading Products 148
ISONEP 148
Corporate Strategy 149
LUX BIOSCIENCES 149
Business Overview 149
Leading Products 149
Luveniq 149
Corporate Strategy 150
MACUSIGHT 150
Website: www.macusight.com/ 150
Business Overview 150
Leading Products 151
Perceiva 151
Corporate Strategy 151
MERCK 151
Business Overview 151
Leading Products 151
Intraocular pressure therapies 151
Corporate Strategy 152
NEUROTECH 152
Business Overview 152
Leading Products 153
Company Strategy 153
NICOX S.A. 153
Business Overview 153
Leading Products 154
NCX 116 154
Corporate Strategy 154
NOVARTIS 154
Business Overview 154
Leading Products 155
Lucentis 155
Visudyne 155
Company Strategy 155
OPKO HEALTH 155
Business Overview 155
Leading Products 156
Bevasiranib 156
Civamide 156
Doxovir 156
Company Strategy 157
OSI PHARMACEUTICALS 157
Business Overview 157
Leading Products 157
Macugen 157
Corporate Strategy 158
OTHERA 158
Business Overview 158
Leading Products 158
Corporate Strategy 159
Business Overview 159
Leading Products 159
Zybrestat 159
Corporate Strategy 159
PFIZER 160
Business Overview 160
Leading Products 160
Xalatan (latanoprost. ophthalmic solution) 160
Corporate Strategy 160
POTENTIA PHARMACEUTICALS 161
Business Overview 161
Leading Products 161
POT-4 161
Corporate Strategy 161
QLT INC. 161
Business Overview 162
Leading Products 162
Visudyne 162
Corporate Strategy 162
PSIVIDA CORPORATION 163
Business Overview 163
Leading Products 163
Iluvien 163
Retisert 163
Corporate Strategy 163
QUARK BIOTECH 164
Business Overview 164
Leading Products 164
PF-4523655 164
Corporate Strategy 164
REGENERON 165
Business Overview 165
Leading Products 165
VEGF-Trap Eye 165
Corporate Strategy 165
SANOFI-AVENTIS 166
Business Overview 166
Leading Products 166
Prednisporin 166
FOV2302 166
Corporate Strategy 167
SANTEN SEIYAKU 167
Business Overview 167
Leading Products 168
Hyalein 168
Cravit/Oftaquix 168
Corporate Strategy 168
SANWA KAGAKU KENKYUSHO CO., LTD 168
Business Overview 168
Leading Products 168
Corporate Strategy 169
SIRION THERAPEUTICS 169
Business Overview 169
Leading Products 169
Durezol 169
Zirgan 169
Corporate Strategy 170
TARGEGEN 170
Business Overview 170
Leading Products 170
TG100801 170
THROMBOGENICS 171
Business Overview 171
Leading Products 171
Microplasmin 171
Corporate Strategy 171
VITREORETINAL TECHNOLOGIES 172
Business Overview 172
Leading Products 172
Vitreosolve 172
Corporate Strategy 172
LEADING UNITED STATES EYE RESEARCH CENTERS 172
MASSACHUSETTS EYE and EAR INFIRMARY 172
Summary 173
BASCOM PALMER EYE INSTITUTE 173
Summary 173
DOHENY EYE INSTITUTE 173
Summary 173
JULES STEIN EYE INSTITUTE 173
Summary 174
THE CULLEN EYE INSTITUTE - BAYLOR COLLEGE OF MEDICINE 174
Summary 174
THE WILMER EYE INSTITUTE AT JOHNS HOPKINS HOSPITAL 174
Summary 174
WILLS EYE HOSPITAL 174
Summary 174
CLAY COUNTY HOSPITAL 175
Summary 175
FORT LAUDERDALE EYE INSTITUTE 175
Summary 175
PHILLIPS EYE INSTITUTE 175
Summary 175
SELECTED GLOBAL EYE HOSPITALS 176
INDIA 176
Aravind Eye Hospital in India 176
Summary 176
Al-Shifa Hospital 176
Summary 176
CHINA 176
He Eye Hospital 176
Summary 177

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Global Pediatric Drugs and Vaccines Market

Global Pediatric Drugs and Vaccines Market

  • $ 4 950
  • Industry report
  • September 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.